Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Assetmark Inc.

Assetmark Inc. grew its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 72.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,271 shares of the company’s stock after acquiring an additional 953 shares during the period. Assetmark Inc.’s holdings in Structure Therapeutics were worth $62,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $40,000. Jones Financial Companies Lllp raised its position in shares of Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock worth $115,000 after purchasing an additional 971 shares during the last quarter. Dearborn Partners LLC acquired a new position in shares of Structure Therapeutics during the 3rd quarter worth approximately $202,000. Finally, Spire Wealth Management purchased a new stake in Structure Therapeutics in the 4th quarter worth approximately $243,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Trading Up 3.2 %

Shares of Structure Therapeutics stock opened at $21.05 on Friday. The company has a fifty day moving average price of $25.31 and a 200 day moving average price of $32.38. Structure Therapeutics Inc. has a twelve month low of $19.39 and a twelve month high of $62.74. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -28.45 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.